Trellis Bioscience, a South San Francisco company that monitors cells at the individual level to assess what sort of treatments to give people, said it has raised $10 million in a second round of financing.

Novartis Bioventures led the round, which included Pac-Link Bio Venture Investment Corporation and Sagamore Bioventures. Previous investors also participated, including Easton-Hunt Capital Partners and Morgenthaler Partners.

Trellis additionally announced that Markus Goebel, M.D., Ph.D., managing director of Novartis Bioventures, will join the Trellis Board of Directors.